Search

for
Search:

Glossary KX826

KX826 is a novel topical treatment developed for androgenetic alopecia, commonly known as male or female pattern hair loss. It functions as a dual-action agent, targeting both the androgen receptors and promoting hair follicle growth, which distinguishes it from traditional treatments like minoxidil and finasteride. Its relevance lies in its potential to offer a more effective solution for hair regrowth by addressing the hormonal factors contributing to hair loss while also stimulating hair follicle activity. Clinical trials have shown promising results, making KX826 a noteworthy option in the evolving landscape of hair loss therapies.

Related Terms

Learn

2 / 801 results

learn KX-826

Kintor Pharmaceutical: KX-826, a New Name in Hair Loss Research KX-826 (pyrilutamide) is an experimental topical androgen receptor blocker from Kintor Pharmaceutical. It is not approved as a medicine anywhere; the company reports that its China Phase III trial met its primary endpoint at 24 weeks, but the trial data has been released through corporate announcements rather than peer-reviewed journals and long-term safety is unknown.

learn Pyrilutamide

highly targeted anti-androgen that might have minimal systemic effects

View more "KX826" in learn →

Community Join

5 / 342 results

community KX826 is better than RU58841. A legitimate option for those who cant use fin or dut.

9 upvotes 5 months ago

KX826 is considered a legitimate option for those who cannot use finasteride or dutasteride, but many users report it as ineffective compared to RU58841. RU58841 is favored by some due to anecdotal evidence of effectiveness, despite the lack of published clinical data.

community kx826 month 10 | topical minoxidil 2 years update.

in Progress Pictures 6 upvotes 1 year ago

The user has been using kx826 for 10 months and topical minoxidil for 2 years, reporting slow but undeniable progress in hair regrowth. They experienced side effects from finasteride and do not use it.

community kx826 .05% month 8 | topical minoxidil .5% month 21 combo update.

in Progress Pictures 6 upvotes 1 year ago

The user used finasteride but stopped due to side effects, then used topical minoxidil for 13 months, and later added KX826/pyrilutamide for 8 months. They experienced shedding after starting pyrilutamide and use minoxidil and KX826 once daily.

community KX826 New Phase 3 Trial In China for 2025: 1.0% concentration

62 upvotes 1 year ago

KX-826 is undergoing Phase III trials in China as a potential treatment for male pattern baldness, with some users considering it as an alternative or addition to finasteride and dutasteride. Opinions on its effectiveness vary, with some users reporting positive results and others finding it expensive and ineffective.

community GT20029 & KX826 Major Updates from Kintor.

101 upvotes 1 year ago

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

View more "KX826" in community →

Research

2 / 1000+ results

Efficacy and Safety of Topical KX-826 in Male Subjects with Androgenetic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study

research 587 Efficacy and Safety of topical KX-826 in Male Subjects with Androgenetic Alopecia:A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study

November 2022 in “Journal of Investigative Dermatology”

Among men with androgenetic alopecia, this study found that taking 5 mg of KX-826 twice daily significantly increased hair count compared to a placebo, with the treatment being well-tolerated and no serious adverse effects reported.

research Emerging pharmacotherapies and regenerative solutions for promoting hair growth for androgenetic alopecia

March 2026 in “Frontiers in Pharmacology”

This study reviews new treatments for androgenetic alopecia, including cell-derived exosomes and investigational drugs, which show potential to improve hair density and quality but require more rigorous and standardized trials to confirm efficacy and safety.

View more "KX826" in research →

Experts

— no results

Try a deeper search in experts →

Clinics

— no results

Try a deeper search in clinics →